Assessing dopaminergic neurotransmission with pet: Basic theory and applications in alcohol research

Current Medical Imaging Reviews

Volumn 7, Issue 2, 2011, Pages 118-124

  Yoder, Karmen K ^a   Kareken, David A ^a   Morris, Evan D ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine d2 receptor; Dopamine release; Neurotransmitter; Position emission tomography; Tracer kinetic modeling

Indexed keywords

ALCOHOL; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; TRACER;

ARTICLE; COGNITION; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; HUMAN; KINETICS; NEUROCHEMISTRY; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

EID: 79955673232     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340511795445694     Document Type: Article

References (55)

1. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27(9): 1533-9.
2. Alpert NM, Badgaiyan RD, Livni E, Fischman AJ. A novel method for noninvasive detection of neuromodulatory changes in specific neurotransmitter systems. Neuroimage 2003; 19(3): 1049-60.
3. Pappata S, Dehaene S, Poline JB, et al. In vivo detection of striatal dopamine release during reward: a PET study with [(11)C]raclopride and a single dynamic scan approach. Neuroimage. 2002; 16(4): 1015-27.
4. Scott DJ, Domino EF, Heitzeg MM, et al. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 2007; 32(2): 450-7.
5. Egerton A, Mehta MA, Montgomery AJ, et al. The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neurosci Biobehav Rev 2009; 33(7): 1109-32.
6. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20(3): 423-51.
7. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007; 55(2): 325-36.
8. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65(2): 220-31.
9. Wager TD, Scott DJ, Zubieta JK. Placebo effects on human muopioid activity during pain. Proc Natl Acad Sci USA 2007; 104(26): 11056-61.
10. Zubieta JK, Ketter TA, Bueller JA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 2003; 60(11): 1145-53.
11. Pinborg LH, Adams KH, Yndgaard S, et al. [18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge. J Cereb Blood Flow Metab 2004; 24(9): 1037-45.
12. Udo de Haes JI, Harada N, Elsinga PH, Maguire RP, Tsukada H. Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: a continuous infusion PET study in conscious monkeys. Synapse 2006; 59(1): 18-26.
13. Wong DF, Brasic JR, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008; 33(6): 1239-51.
14. Finnema SJ, Varrone A, Hwang TJ, et al. Fenfluramine decreases 5-H1B binding of [11C]AZ10419369 in the primate brain. Journal of Cerebral Blood Flow & Metabolism 2009; 29: S66.
15. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989; 3(1): 96-7.
16. Young LT, Wong DF, Goldman S, et al. Effects of endogenous dopamine on kinetics of[3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse 1991; 9(3): 188-94.
17. Dewey S, Smith G, Logan J, Brodie J, Fowler J, Wolf A. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993; 13: 350-6.
18. Dewey S, Smith G, Logan J, et al. GABAergic inhibition of endogenous dopamine release measure in vivo with 11C-raclopride and positron emission tomography. J Neurosci 1992; 12: 3773-80.
19. Dewey SL, Smith GS, Logan J, et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 1993; 90(24): 11816-20.
20. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94(6): 2569-74.
21. Laruelle M, Abi-Dargham A, van Dyck C, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-40.
22. Laruelle M, Huang Y. Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Q J Nucl Med 2001; 45(2): 124-38.
23. Morris ED, Yoder KK. Positron emission tomography displacement sensitivity: predicting binding potential change for positron emission tomography tracers based on their kinetic characteristics. J Cereb Blood Flow Metab 2007; 27(3): 606-17.
24. Endres CJ, Carson RE. Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands. J Cereb Blood Flow Metab 1998; 18(11): 1196-210.
25. Yoder KK, Wang C, Morris ED. Change in binding potential as a quantitative index of neurotransmitter release is highly sensitive to relative timing and kinetics of the tracer and the endogenous ligand. J Nucl Med 2004; 45(5): 903-11.
26. Morris ED, Fisher RE, Alpert NM, Rauch SL, Fischman AJ. In vivo imaging of neuromodulation using positron emission tomography: optimal ligand characteristics and task length for detection of activation. Human Brain Mapping 1995; 3: 35-55.
27. Morris ED, Heidbreder CA, Shippenberg TS, Ernst M, Christian BT, London ED. Can PET detect changes in intrasynaptic dopamine? Computer simulations can optimize the experimental design. Society for Neuroscience. 1996;Washington, D.C.
28. O'Connor S, Morzorati S, Christian J, Li TK. Clamping breath alcohol concentration reduces experimental variance: application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res 1998; 22(1): 202-10.
29. Ramchandani VA, Bolane J, Li TK, O'Connor S. A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol Clin Exp Res 1999; 23(4): 617-23.
30. Friel PN, Baer JS, Logan BK. Variability of ethanol absorption and breath concentrations during a large-scale alcohol administration study. Alcohol Clin Exp Res 1995; 19(4): 1055-60.
31. Holford NH. Clinical pharmacokinetics of ethanol. Clin Pharmacokinet 1987; 13(5): 273-92.
32. Pikaar NA, Wedel M, Hermus RJ. Influence of several factors on blood alcohol concentrations after drinking alcohol. Alcohol Alcohol 1988; 23(4): 289-97.
33. Salonen I, Hietala J, Laihinen A, et al. A PET study on the acute effect of ethanol on striatal D2 dopamine receptors with [11C]raclopride in healthy males. Human Psychopharmacology 1997; 12: 142-52.
34. Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003; 49(4): 226-31.
35. Urban NB, Kegeles LS, Slifstein M, et al. Sex Differences in Striatal Dopamine Release in Young Adults After Oral Alcohol Challenge: A Positron Emission Tomography Imaging Study With [(11)C]Raclopride. Biol Psychiatry 2010 Jul 31.
36. Doyon WM, Anders SK, Ramachandra VS, Czachowski CL, Gonzales RA. Effect of operant self-administration of 10% ethanol plus 10% sucrose on dopamine and ethanol concentrations in the nucleus accumbens. J Neurochem 2005; 93(6): 1469-81.
37. Doyon WM, York JL, Diaz LM, Samson HH, Czachowski CL, Gonzales RA. Dopamine activity in the nucleus accumbens during consummatory phases of oral ethanol self-administration. Alcohol Clin Exp Res 2003; 27(10): 1573-82.
38. Yoder KK, Constantinescu CC, Kareken DA, et al. Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study. Alcohol Clin Exp Res 2007; 31(6): 965-73.
39. Ramchandani VA, Umhau J, Pavon FJ, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 2010 May 18.
40. Yoder KK, Kareken DA, Morris ED. What were they thinking? Cognitive states may influence [(11)C]raclopride binding potential in the striatum. Neurosci Lett 2008; 430(1): 38-42.
41. de la Fuente-Fernandez R, Phillips AG, Zamburlini M, et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002; 136(2): 359-63.
42. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293(5532): 1164-6.
43. Kaasinen V, Aalto S, Nagren K, Rinne JO. Expectation of caffeine induces dopaminergic responses in humans. Eur J Neurosci 2004; 19(8): 2352-6.
44. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998; 80(1): 1-27.
45. Yoder KK, Kareken DA, Seyoum RA, et al. Dopamine D(2) receptor availability is associated with subjective responses to alcohol. Alcohol Clin Exp Res 2005; 29(6): 965-70.
46. Badgaiyan RD, Fischman AJ, Alpert NM. Striatal dopamine release during unrewarded motor task in human volunteers. Neuroreport 2003; 14(11): 1421-4.
47. Constantinescu CC, Yoder KK, Kareken DA, et al. Estimation from PET data of transient changes in dopamine concentration induced by alcohol: support for a non-parametric signal estimation method. Phys Med Biol 2008; 53(5): 1353-67.
48. Morris ED, Constantinescu CC, Sullivan JM, Normandin MD, Christopher LA. Noninvasive visualization of human dopamine dynamics from PET images. Neuroimage 2010; 51(1): 135-44.
49. Morris ED, Yoder KK, Wang C, et al. ntPET: A New Application of PET Imaging for Characterizing the Kinetics of Endogenous Neurotransmitter Release. Mol Imaging 2005; 4(4): 473-89.
50. Normandin MD, Morris ED. Estimating neurotransmitter kinetics with ntPET: a simulation study of temporal precision and effects of biased data. Neuroimage 2008; 39(3): 1162-79.
51. Badgaiyan RD, Fischman AJ, Alpert NM. Striatal dopamine release in sequential learning. Neuroimage 2007; 38(3): 549-56.
52. Narendran R, Frankle WG, Mason NS, et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse 2009; 63(6): 447-61.
53. Vandehey NT, Moirano JM, Converse AK, et al. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. J Cereb Blood Flow Metab 2010; 30(5): 994-1007.
54. Ginovart N, Galineau L, Willeit M, et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 2006; 97(4): 1089-103.
55. Carson RE. Mathematical modeling and compartmental analysis. In: Harbert JC, Eckelman WC, Neumann RD, editors. Nuclear Medicine: Diagnosis and Therapy. New York: Thieme Medical Publishers, Inc.; 1996. p. 167-93.